Previous Mistakes with DCB Technology, and How to Prevent Them in the Future
Drug-coated balloon (DCB) is a relatively novel device for coronary and peripheral artery disease management . It consists in a conventional balloon angioplasty covered by an antiproliferative drug. This technology allows to bring high concentration of an antiproliferative drug with rapid local delivery without the implantation of an external prosthesis like a metal stent or a scaffold, technologies associated with some late-occurring thrombotic events. In this light, the shorter dual antiplatelet therapy (DAPT) duration usually required with DCB may be an advantage because it warrants a reduced bleeding risk, especially in high-risk and compromised patients.
- 6.Kufner S, Joner M, Schneider S, Tölg R, Zrenner B, Repp J, Starkmann A, Xhepa E, Ibrahim T, Cassese S, Fusaro M, Ott I, Hengstenberg C, Schunkert H, Abdel-Wahab M, Laugwitz KL, Kastrati A, Byrne RA, ISAR-DESIRE 4 Investigators. Neointimal modification with scoring balloon and efficacy of drug-coated balloon therapy in patients with restenosis in drug-eluting coronary stents: a randomized controlled trial. JACC Cardiovasc Interv. 2017;10:1332–40.CrossRefGoogle Scholar
- 9.Mitomo S, Mangieri A, Regazzoli D, Ancona M, Giannini F, Chieffo A, Montorfano M, Latib A, Colombo A. TCT-526 mid-term clinical outcomes after bailout stenting with drug-eluting stent for suboptimal results of drug-coated balloon; Milan registry. J Am Coll Cardiol. 2017;70(18 Supplement):B218. https://doi.org/10.1016/j.jacc.2017.09.697.CrossRefGoogle Scholar